Cytek Biosciences Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 3.56, above the company average. This is a clear sign of healthy business climate in the Laboratory Analytical Instruments industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Cytek Biosciences Inc in Mar 31 2026 quarter, has decreased to 103 days, compared to 105 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 318 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 2224, from overall ranking in the fourth quarter 2025 at 2705.

What is Receivable Turnover Ratio?
What is Cytek Biosciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CTKB Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-5.68 %	3.17 %	7.6 %	25.96 %	9.39 %
Y / Y Revenue Change	5.1 %	5.95 %	1.07 %	-1.8 %	-6.49 %
Receivable Turnover Ratio (TTM)	3.56	3.48	3.45	3.5	3.71
CTKB's Total Ranking	# 2224	# 2705	# 1926	# 2971	#
Accounts Receivable average collection period days	102	105	106	104	98
Seq. Receivable Change	-16.97 %	10.38 %	0.71 %	2.19 %	-9.18 %
Seq. Revenue Change	-30.39 %	20.54 %	13.05 %	10.8 %	-29.83 %

Receivable Turnover Company Ranking
Within:	No.
Laboratory Analytical Instruments Industry	# 12
Healthcare Sector	# 319
Overall Market	# 2224

Receivable Turnover Ratio Statistics
High	Average	Low
0.43	0.37	0.31
(Mar 31 2026)		(Jun 30 2022)

CTKB Company Profile • Back to CTKB Efficiency Comparisons • Compare CTKB Receivables Turnover Ratio to its Competitors

Financial Statements
Cytek Biosciences Inc 's Accounts Receivable	$ 52 Millions	Visit CTKB's Balance sheet
Cytek Biosciences Inc 's Sales TTM	$ 203 Millions	Visit CTKB's Income Statement
Sources of CTKB's Revenues		Visit CTKB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Laboratory Analytical Instruments Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CTKB's Receivable Turnover Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CTKB's Growth Rates	CTKB's Roa	CTKB's Inventory Turnover Ratio	CTKB's Dividend Comparisons
CTKB's Profitability Ratios	CTKB's Roi	CTKB's Asset Turnover Ratio	CTKB's Dividend Growth
CTKB's Valuation Ratios	CTKB's Roe	CTKB's Financial Strength Ratios	CTKB's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Vivos Therapeutics Inc	10.73	$ 19.092 Millions	$ 1.779 Millions
Veracyte Inc	10.68	$ 516.183 Millions	$ 48.353 Millions
Immucell Corporation	10.51	$ 29.035 Millions	$ 2.762 Millions
Kestra Medical Technologies Ltd	10.51	$ 93.819 Millions	$ 8.925 Millions
Lifeloc Technologies Inc	10.41	$ 9.044 Millions	$ 0.869 Millions
Monte Rosa Therapeutics Inc	10.39	$ 42.953 Millions	$ 4.136 Millions
International Stem Cell Corporation	10.23	$ 9.286 Millions	$ 0.908 Millions
Pavmed Inc	10.19	$ 0.107 Millions	$ 0.011 Millions
Viemed Healthcare Inc	10.16	$ 286.565 Millions	$ 28.217 Millions
Addus Homecare Corp	10.14	$ 1,447.070 Millions	$ 142.667 Millions
Utah Medical Products Inc	10.13	$ 36.745 Millions	$ 3.629 Millions
Petvivo Holdings Inc	10.10	$ 0.821 Millions	$ 0.081 Millions
Irhythm Holdings Inc	10.00	$ 787.387 Millions	$ 78.720 Millions
C4 Therapeutics Inc	9.97	$ 34.861 Millions	$ 3.496 Millions
Biodesix Inc	9.94	$ 96.096 Millions	$ 9.665 Millions
Radnet Inc	9.87	$ 2,144.442 Millions	$ 217.223 Millions
Lensar Inc	9.87	$ 57.704 Millions	$ 5.847 Millions
X4 Pharmaceuticals Inc	9.69	$ 9.014 Millions	$ 0.931 Millions
Septerna Inc	9.64	$ 72.255 Millions	$ 7.499 Millions
Encompass Health Corporation	9.63	$ 6,066.400 Millions	$ 629.625 Millions
Biolife Solutions Inc	9.51	$ 99.673 Millions	$ 10.478 Millions
Biofrontera Inc	9.49	$ 42.983 Millions	$ 4.530 Millions
United Therapeutics Corporation	9.47	$ 3,169.800 Millions	$ 334.800 Millions
Tandem Diabetes Care Inc	9.34	$ 1,023.420 Millions	$ 109.550 Millions
Sunshine Biopharma Inc	9.33	$ 35.493 Millions	$ 3.804 Millions
The Oncology Institute Inc	9.30	$ 545.764 Millions	$ 58.671 Millions
The Pennant Group Inc	9.28	$ 1,023.227 Millions	$ 110.305 Millions
Enanta Pharmaceuticals Inc	9.26	$ 69.213 Millions	$ 7.477 Millions
Volitionrx Limited	9.23	$ 2.466 Millions	$ 0.267 Millions
Lucid Diagnostics Inc	9.11	$ 5.134 Millions	$ 0.564 Millions

Date modified: 2026-08-29T17:45:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.